Priyanka Sharma, MD

Professional Background

Dr. Priyanka Sharma is a Professor of Medicine at the University of Kansas Medical Center and assistant director of clinical research and co-program leader for the Drug Discovery, Delivery & Experimental Therapeutics program at the University of Kansas Cancer Center. She is the institutional principal investigator for South West Oncology Group (SWOG) and co-PI for MCA-KUCC NCORP grant.

Dr. Sharma received her medical degree from MS University of Baroda, India and proceeded to complete Internal Medicine residency, chief residency, and Hematology-Oncology fellowship at the University of Kansas Medical Center. Her research interests include clinical and translational research in triple-negative breast cancer (TNBC) and novel treatment strategies for metastatic breast cancer.

Dr. Sharma is recipient of several grants including American Society of Clinical Oncology (ASCO) Advanced Clinical Research Award, Mary-Kay Foundation grant and is principle investigator of several ongoing clinical trials with targeted agents.

Dr. Sharma is Vice-Chair of the South West Oncology Group (SWOG) Breast Committee, member of SWOG Board of Governors and member of NCI breast cancer steering committee.

• MBBS, University of Baroda, Baroda, Gujurat
• Internship, Rural Health Service and Obstetrics/Gynecology, Baroda Medical College, Baroda , Gujurat
• Internship, Community Health Service and Internal Medicine, Baroda Medical College, Baroda, Gujurat
• Residency, Department of Internal Medicine, University of Kansas School of Medicine, Kansas City, KS
• Residency, Department of Internal Medicine, University of Kansas School of Medicine, Kansas City, KS
• Clinical Fellowship, Division of Hematology/Oncology, University of Kansas School of Medicine, Kansas City, KS

• American Board of Internal Medicine - Medical Oncology
• Kansas

• Southwest Oncology Group, SWOG Breast Committee, Vice Chair, 2018 - Present
• American Society of Clinical Oncology, American Society of Clinical Oncology, Member, 2001 - Present

---

Research

Overview

I am a Professor of Medicine in the Department of Internal Medicine, Division of Oncology, as well as the Assistant Director for Clinical Research within the University of Kansas Cancer Center (KUCC). I am the Vice-Chair of the SWOG Breast Committee and have been member of the SWOG Board of Governors since 2015. I am a member of the American Society of Clinical Oncology (ASCO) scientific program committee, for which I also serve as breast cancer track leader for 2018-2019. In addition to national and institutional leadership roles, I am very actively involved in clinical and translational breast cancer research. My long-term research goal is to delineate personalized treatment strategies for triple-negative breast cancer (TNBC) and BRCA mutation-associated breast cancer. I serve as Translational PI of an ongoing CTEP-funded SWOG trial for patients with TNBC (S1416) and as PI of an active translational SWOG study (S9313c) which also focuses on TNBC. Outside of SWOG I have served as PI of several neoadjuvant therapeutic investigator-initiated trials for TNBC.

• DDIR/HRD status predicts response to chemoimmunotherapy in TNBC, Department of Defense, PI
• Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study., SWOG, PI
• The University of Kansas Cancer Center - Midwest Cancer Alliance Rural NCORP (KUCC-MCA Rural NCORP), NCI Community Oncology Research Program (NCORP) Minority/Underserved Community Sites UG1, Co-PI
• Phase II trial of Neoadjuvant Carboplatin, Docetaxel plus Pembrolizumab in Stage I-III Triple-Negative Breast Cancer (NeoPACT), Merck & Co, Inc., PI
• Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without Veliparib (ABT-888) in Metastatic Triple-Negative Breast Cancer and BRCA Mutation-Associated Breast Cancer, SWOG, PI
• Evaluation of BRCAness as Prognostic Marker in Triple Negative Breast Cancer Patients Treated with Adjuvant Anthracycline Based Chemotherapy, Breast Cancer Research Foundation, PI
• Phase I/II trial of Nab-Paclitaxel and BYL-719 in Women with HER2 Negative Locally Recurrent or Metastatic Breast Cancer, Novartis Oncology, PI

• Sharma Priyanka, Kimler Bruce F, O'Dea Anne, Nye Lauren, Wang Yen Y, Yoder Rachel, Staley Joshua M, Prochaska Lindsey, Wagner Jamie, Amin Amanda L, Larson Kelsey, Balanoff Christa, Elia Manana, Crane Gregory, Madhusudhana Sheshadri, Hoffmann Marc, Sheehan Maureen, Rodriguez Roberto, Finke Karissa, Shah Rajvi, Satelli Deepti, Shrestha Anuj, Beck Larry, McKittrick Richard, Pluenneke Robert, Raja Vinay, Beeki Venkatadri, Corum Larry, Heldstab Jaimie, LaFaver Stephanie, Prager Micki, Phadnis Milind, Mudaranthakam Dinesh Pal, Jensen Roy A, Godwin Andrew K, Salgado Roberto, Mehta Kathan, Khan Qamar. 2021. Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I-III Triple-negative Breast Cancer (NeoSTOP).. Clinical Cancer Research, 27 (4), 975-982. https://doi.org/10.1158/1078-0432.ccr-20-3646
• Rodler Eve, Sharma Priyanka, Barlow William E, Gralow Julie R, Puhalla Shannon L, Anders Carey K, Goldstein Lori, Tripathy Debu, Brown-Glaberman Ursa A, Huynh Thu-Tam, Szyarto Christopher S, Godwin Andrew K, Pathak Harsh B, Swisher Elizabeth M, Radke Marc R, Timms Kirsten M, Lew Danika L, Miao Jieling, Pusztai Lajos, Hayes Daniel F, Hortobagyi Gabriel N. 2023. Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial.. The Lancet Oncology, 24 (2), 162-174. https://doi.org/10.1016/s1470-2045(22)00739-2
• Sharma Priyanka, Barlow William E, Godwin Andrew K, Parkes Eileen E, Knight Laura A, Walker Steven M, Kennedy Richard D, Harkin Denis P, Logan Gemma E, Steele Christopher J, Lambe Shauna M, Badve Sunil, Gökmen-Polar Yesim, Pathak Harsh B, Isakova Kamilla, Linden Hannah M, Porter Peggy, Pusztai Lajos, Thompson Alastair M, Tripathy Debu, Hortobagyi Gabriel N, Hayes Daniel F. 2019. Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial.. Journal of Clinical Oncology, 37 (36), 3484-3492. https://doi.org/10.1200/jco.19.00693
• Sharma Priyanka, Stecklein Shane R, Yoder Rachel, Staley Joshua M, Schwensen Kelsey, O’Dea Anne, Nye Lauren, Satelli Deepti, Crane Gregory, Madan Rashna, O’Neil Maura F, Wagner Jamie, Larson Kelsey E, Balanoff Christa, Kilgore Lyndsey, Phadnis Milind A, Godwin Andrew K, Salgado Roberto, Khan Qamar J, O’Shaughnessy Joyce. 2024. Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer. JAMA Oncology, 10 (2), 227. https://doi.org/10.1001/jamaoncol.2023.5033
• Sharma Priyanka, Klemp Jennifer R, Kimler Bruce F, Mahnken Jonathan D, Geier Larry J, Khan Qamar J, Elia Manana, Connor Carol S, McGinness Marilee K, Mammen Joshua M, Wagner Jamie L, Ward Claire, Ranallo Lori, Knight Catherine J, Stecklein Shane R, Jensen Roy A, Fabian Carol J, Godwin Andrew K. 2014. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing. Breast Cancer Research and Treatment, 145 (3), 707-714. https://doi.org/10.1007/s10549-014-2980-0
• Connor C. S, Kimler B. F, Mammen J. M, McGinness M. K, Wagner J. L, Alsop S. M, Ward C., Fabian C. J, Khan Q. J, Sharma P.. 2015. Impact of neoadjuvant chemotherapy on axillary nodal involvement in patients with clinically node negative triple negative breast cancer. Journal of Surgical Oncology, 111 (2), 198-202. https://doi.org/10.1002/jso.23790
• Sharma P, Barlow W, Godwin A. K, Pathak H., Isakova K, Hartman AR, TImms KM, Linden JM, Tripathy D., Hortobagyi G.N, Hayes D. F. 2017. Impact of homologous recombination deficiency (HRD) biomarkers on outcomes in triple negative breast cancer (TNBC) patients treated with AC chemotherapy (SWOG S9313) [abstract]. Cancer Res, 77 (13 Suppl), Abstract nr 1776. http://cancerres.aacrjournals.org/content/77/13_Supplement/1776
• Yoder Rachel, Kimler Bruce F, Staley Joshua M, Schwensen Kelsey, Wang Yen Y, Finke Karissa, O’Dea Anne, Nye Lauren, Elia Manana, Crane Gregory, McKittrick Richard, Pluenneke Robert, Madhusudhana Sheshadri, Beck Larry, Shrestha Anuj, Corum Larry, Marsico Mark, Stecklein Shane R, Godwin Andrew K, Khan Qamar J, Sharma Priyanka. 2022. Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer.. NPJ breast cancer, 8 (1), 80. https://doi.org/10.1038/s41523-022-00448-4
• Sharma Priyanka, López-Tarruella Sara, García-Saenz Jose Angel, Ward Claire, Connor Carol S, Gómez Henry L, Prat Aleix, Moreno Fernando, Jerez-Gilarranz Yolanda, Barnadas Augusti, Picornell Antoni C, del Monte-Millán Maria, Gonzalez-Rivera Milagros, Massarrah Tatiana, Pelaez-Lorenzo Beatriz, Palomero María Isabel, González del Val Ricardo, Cortes Javier, Fuentes Rivera Hugo, Bretel Morales Denisse, Márquez-Rodas Iván, Perou Charles M, Wagner Jamie L, Mammen Joshua M.V, McGinness Marilee K, Klemp Jennifer R, Amin Amanda L, Fabian Carol J, Heldstab Jaimie, Godwin Andrew K, Jensen Roy A, Kimler Bruce F, Khan Qamar J, Martin Miguel. 2017. Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts. Clinical Cancer Research, 23 (3), 649-657. https://doi.org/10.1158/1078-0432.ccr-16-0162
• Sharma Priyanka, López-Tarruella Sara, García-Saenz José Angel, Khan Qamar J, Gómez Henry L, Prat Aleix, Moreno Fernando, Jerez-Gilarranz Yolanda, Barnadas Agustí, Picornell Antoni C, Monte-Millán María del, González-Rivera Milagros, Massarrah Tatiana, Pelaez-Lorenzo Beatriz, Palomero María Isabel, González del Val Ricardo, Cortés Javier, Fuentes-Rivera Hugo, Morales Denisse Bretel, Márquez-Rodas Iván, Perou Charles M, Lehn Carolyn, Wang Yen Y, Klemp Jennifer R, Mammen Joshua V, Wagner Jamie L, Amin Amanda L, O’Dea Anne P, Heldstab Jaimie, Jensen Roy A, Kimler Bruce F, Godwin Andrew K, Martín Miguel. 2018. Pathological response and survival in triple-negative breast cancer following neoadjuvant carboplatin plus docetaxel. Clinical Cancer Research, 24 (23), 5820-5829. https://doi.org/10.1158/1078-0432.ccr-18-0585